Oncology · GlioblastomaOtherclinicalmid-term

Systematic review on EGFR alterations in recurrent glioblastoma therapy response

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/20/2026, 6:31:45 AM

Assessment confidence: 48% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The findings from this systematic review highlight the importance of EGFR alterations as potential predictive biomarkers in glioblastoma therapy. This could significantly influence clinical development strategies and treatment protocols for recurrent glioblastoma, impacting patient outcomes and market positioning. Regulatory context from FDA (BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act) supports the near-term read. Assessment grounded in 24 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea (ClinicalTrials.gov), patient population match (recurrent). In Oncology · Glioblastoma, 4 regulatory and 4 competitive items passed relevance filtering for clinical trial sponsors. As understanding of predictive biomarkers evolves, companies that adapt their development strategies may capture greater market share in the competitive glioblastoma therapy landscape.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study. Understanding the predictive biomarkers for therapy response could influence treatment strategies and drug development in glioblastoma.

Regulatory Outlook

Regulatory risk is concentrated around BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The insights gained from this review may inform regulatory submissions and labeling for EGFR-targeted therapies, potentially affecting approval timelines and market access.

Key Risks

Elevated medium regulatory exposure for clinical trial sponsors could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on clinical trial sponsors through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

As understanding of predictive biomarkers evolves, companies that adapt their development strategies may capture greater market share in the competitive glioblastoma therapy landscape.
Upside for clinical trial sponsors may improve if A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Esophageal Squamous Cell Carcinoma · Trial Update · This trial could position the combination therapy as a leading treatment option for LAEC, potentially impacting existing treatment protocols and competitive positioning of current therapies.
Upside for clinical trial sponsors may improve if The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants. (PubMed) delivers favorable follow-through.
The implications of EGFR alterations in their clinical development plans for glioblastoma therapies.

What Would Change This Assessment

This becomes more urgent if Monitor ongoing studies that further investigate the role of EGFR alterations in treatment outcomes for glioblastoma.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Update on the PATHWAYS clinical trial
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
ClinicalTrials.gov: Essentials for Academic Medical Centers - 07/14/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govhigh relevance
Patient population match (recurrent)
FDA document
View source
A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.
PubMedhigh relevance
Mechanism alignment (EGFR); Patient population match (recurrent)
FDA document
View source
Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
NK cell-based immunotherapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical trial sponsors
recurrent glioblastoma treatments
oncology drug developers

Commercial impact

medium

As understanding of predictive biomarkers evolves, companies that adapt their development strategies may capture greater market share in the competitive glioblastoma therapy landscape.

Regulatory impact

medium

The insights gained from this review may inform regulatory submissions and labeling for EGFR-targeted therapies, potentially affecting approval timelines and market access.

What to watch

Monitor ongoing studies that further investigate the role of EGFR alterations in treatment outcomes for glioblastoma.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.